401 related articles for article (PubMed ID: 17289807)
1. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease.
Zohn IE; De Domenico I; Pollock A; Ward DM; Goodman JF; Liang X; Sanchez AJ; Niswander L; Kaplan J
Blood; 2007 May; 109(10):4174-80. PubMed ID: 17289807
[TBL] [Abstract][Full Text] [Related]
2. Ferroportin deficiency impairs manganese metabolism in flatiron mice.
Seo YA; Wessling-Resnick M
FASEB J; 2015 Jul; 29(7):2726-33. PubMed ID: 25782988
[TBL] [Abstract][Full Text] [Related]
3. The molecular basis of ferroportin-linked hemochromatosis.
De Domenico I; Ward DM; Nemeth E; Vaughn MB; Musci G; Ganz T; Kaplan J
Proc Natl Acad Sci U S A; 2005 Jun; 102(25):8955-60. PubMed ID: 15956209
[TBL] [Abstract][Full Text] [Related]
4. Flatiron mice and ferroportin disease.
Johnson EE; Wessling-Resnick M
Nutr Rev; 2007 Jul; 65(7):341-5. PubMed ID: 17695375
[TBL] [Abstract][Full Text] [Related]
5. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.
Schimanski LM; Drakesmith H; Merryweather-Clarke AT; Viprakasit V; Edwards JP; Sweetland E; Bastin JM; Cowley D; Chinthammitr Y; Robson KJ; Townsend AR
Blood; 2005 May; 105(10):4096-102. PubMed ID: 15692071
[TBL] [Abstract][Full Text] [Related]
6. Evidence for the multimeric structure of ferroportin.
De Domenico I; Ward DM; Musci G; Kaplan J
Blood; 2007 Mar; 109(5):2205-9. PubMed ID: 17077321
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of the functional properties of human and mouse ferroportin.
Azucenas CR; Ruwe TA; Bonamer JP; Qiao B; Ganz T; Jormakka M; Nemeth E; Mackenzie B
Am J Physiol Cell Physiol; 2023 May; 324(5):C1110-C1118. PubMed ID: 36939203
[TBL] [Abstract][Full Text] [Related]
8. Distribution of manganese and other biometals in flatiron mice.
Seo YA; Elkhader JA; Wessling-Resnick M
Biometals; 2016 Feb; 29(1):147-55. PubMed ID: 26693922
[TBL] [Abstract][Full Text] [Related]
9. Ferroportin diseases: functional studies, a link between genetic and clinical phenotype.
Détivaud L; Island ML; Jouanolle AM; Ropert M; Bardou-Jacquet E; Le Lan C; Mosser A; Leroyer P; Deugnier Y; David V; Brissot P; Loréal O
Hum Mutat; 2013 Nov; 34(11):1529-36. PubMed ID: 23943237
[TBL] [Abstract][Full Text] [Related]
10. The ferroportin disease.
Pietrangelo A
Blood Cells Mol Dis; 2004; 32(1):131-8. PubMed ID: 14757427
[TBL] [Abstract][Full Text] [Related]
11. Wild-type and mutant ferroportins do not form oligomers in transfected cells.
Gonçalves AS; Muzeau F; Blaybel R; Hetet G; Driss F; Delaby C; Canonne-Hergaux F; Beaumont C
Biochem J; 2006 Jun; 396(2):265-75. PubMed ID: 16457665
[TBL] [Abstract][Full Text] [Related]
12. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.
Aschemeyer S; Qiao B; Stefanova D; Valore EV; Sek AC; Ruwe TA; Vieth KR; Jung G; Casu C; Rivella S; Jormakka M; Mackenzie B; Ganz T; Nemeth E
Blood; 2018 Feb; 131(8):899-910. PubMed ID: 29237594
[TBL] [Abstract][Full Text] [Related]
13. Evidence for dimerization of ferroportin in a human hepatic cell line using proximity ligation assays.
Rishi G; Secondes ES; Wallace DF; Subramaniam VN
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32301493
[TBL] [Abstract][Full Text] [Related]
14. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin.
Drakesmith H; Schimanski LM; Ormerod E; Merryweather-Clarke AT; Viprakasit V; Edwards JP; Sweetland E; Bastin JM; Cowley D; Chinthammitr Y; Robson KJ; Townsend AR
Blood; 2005 Aug; 106(3):1092-7. PubMed ID: 15831700
[TBL] [Abstract][Full Text] [Related]
15. Iron overload due to mutations in ferroportin.
De Domenico I; Ward DM; Musci G; Kaplan J
Haematologica; 2006 Jan; 91(1):92-5. PubMed ID: 16434376
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice.
Taylor M; Qu A; Anderson ER; Matsubara T; Martin A; Gonzalez FJ; Shah YM
Gastroenterology; 2011 Jun; 140(7):2044-55. PubMed ID: 21419768
[TBL] [Abstract][Full Text] [Related]
17. Human mutation D157G in ferroportin leads to hepcidin-independent binding of Jak2 and ferroportin down-regulation.
De Domenico I; Lo E; Ward DM; Kaplan J
Blood; 2010 Apr; 115(14):2956-9. PubMed ID: 20124516
[TBL] [Abstract][Full Text] [Related]
18. Ferroportin disease mutations influence manganese accumulation and cytotoxicity.
Choi EK; Nguyen TT; Iwase S; Seo YA
FASEB J; 2019 Feb; 33(2):2228-2240. PubMed ID: 30247984
[TBL] [Abstract][Full Text] [Related]
19. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis.
Donovan A; Lima CA; Pinkus JL; Pinkus GS; Zon LI; Robine S; Andrews NC
Cell Metab; 2005 Mar; 1(3):191-200. PubMed ID: 16054062
[TBL] [Abstract][Full Text] [Related]
20. The cardinal roles of ferroportin and its partners in controlling cellular iron in and out.
Yang Q; Liu W; Zhang S; Liu S
Life Sci; 2020 Oct; 258():118135. PubMed ID: 32712297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
